N/A N=80 Safety and Effectiveness of Sculptra Aesthetic for Correction of Nasolabial Folds.
Nasolabial Folds
Primary: Change in Wrinkle Assessment Scale (WAS) Score — -1.3; -1.3; -1.2; -1.3 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 Pharmacokinetic-pharmacodynamic Analysis of Sugammadex in Children
Anesthesia, General · Neuromuscular Blockade
Primary: Neuromuscular Recovery — 5.7; 3.1; 1.1; 43.7 Minutes
Phase 2 N=185 Urinary Track Infection Prevention After Urogynecological Surgery
Urinary Tract Infections · Urinary Retention Postoperative · Pelvic Organ Prolapse
Primary: Incidence of Urinary Track Infection (UTI) — 62; 71 Participants
N/A N=29 Preliminary Study 1 to Test the Effects of Ambulatory Voice Biofeedback
Vocal Fold Nodules
Primary: Percent Compliance — 97.38; 95.11; 94.44; 96.08 Percentage of voicing below a threshold
N/A N=27 Asthma and Obesity: Pilot Study
Asthma · Obesity
Primary: Beliefs About Illness Perception Questionnaire (BIPQ) — 42.6; 36.2 score on a scale
Phase 2 N=118 Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)
Non-Small Cell Lung Cancer
Primary: Objective Response Rate — 40.2 Percentage of Participants
N/A N=324 Partial Breast Irradiation (PBI) for Selected Patients With Early Invasive or Non-Invasive Breast Cancer
Ductal Breast Cancer
Primary: Feasibility and Local Control of Early Breast Cancer Treated by Partial Breast Irradiation Using Different Radiation Doses Determined by Completion. — 98; 101; 124…
Phase 3 N=3,307 A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
Osteoarthritis, Knee · Osteoarthritis, Hip
Primary: Change in the WOMAC Pain Subscale Scores From Baseline to Week 16 in Participants Treated With Fasinumab 1mg SC Q4W Compared With That of Participants Treated With…
Phase 2 N=29 Lenalidomide in Treating Patients With High Risk Acute Myeloid Leukemia in Remission
Alkylating Agent-Related Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia
Primary: Relapse-free Survival (RFS) — 21.5 Months
Phase 4 N=70 Vascular Inflammation in Psoriasis - Apremilast
Psoriasis · Cardiovascular Diseases
Primary: Change in Total Vascular Inflammation of the Aorta as Measured by FDG-PET/CT Between Baseline and Week 16. — -0.017 ratio — p=0.612
Phase 2 N=10 Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma
Stage III Cutaneous Melanoma AJCC v7 · Stage IIIA Cutaneous Melanoma AJCC v7 · Stage IIIB Cutaneous Melanoma AJCC v7
Primary: Number of Participants in Each Clinical Response Category — 2; 2; 2; 4 Participants
Phase 2 N=45 St. PETERsburg Pain and Alcohol Intervention With Naltrexone and Gabapentin
Chronic Pain · Alcohol Use, Unspecified · HIV Infections
Primary: Change in Past Week Pain Severity — -0.97; -2.12; -1.85 units on a scale
Phase 1 N=7 A Study of Tazemetostat in Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Primary: Number of Participants With Dose-limiting Toxicities (DLTs) — 0 Participants
N/A N=38 Unlocking Dystonia From Parkinson's Disease With Directional DBS Technology
Dystonia-Parkinsonism, Adult-Onset · Parkinson Disease
Primary: Burke-Fahn-Marsden Dystonia Rating Scale — 3.5 units on a scale — p=<0.001
N/A N=20 Healthy Patients & Effect of Antibiotics
Microbiota · Anti-bacterial Agents
Primary: Degree of Microbial Disruption: Number of Patients With Recovery of Bacterial Species Richness at 185 Days Post-antibiotics — 3; 3; 2; 3 Participants